Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study

Gemcitabine is a key drug for the treatment of pancreatic cancer; however, with its limitation in clinical benefits, the development of another potent therapeutic is necessary. Vascular endothelial growth factor receptor 2 is an essential target for tumor angiogenesis, and we have conducted a phase...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Sci
Päätekijät: Yamaue, Hiroki, Tsunoda, Takuya, Tani, Masaji, Miyazawa, Motoki, Yamao, Kenji, Mizuno, Nobumasa, Okusaka, Takuji, Ueno, Hideki, Boku, Narikazu, Fukutomi, Akira, Ishii, Hiroshi, Ohkawa, Shinichi, Furukawa, Masayuki, Maguchi, Hiroyuki, Ikeda, Masafumi, Togashi, Yosuke, Nishio, Kazuto, Ohashi, Yasuo
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Ltd 2015
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4520640/
https://ncbi.nlm.nih.gov/pubmed/25867139
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12674
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia